Top Markets
Coin of the day
VectivBio Holding AG VectivBio Holding AG

VectivBio Holding AG

VECT
Rang in aandelen #14772
VectivBio Holding AG is a clinical-stage biopharmaceutical firm committed to... VectivBio Holding AG is a clinical-stage biopharmaceutical firm committed to identifying, developing, and commercializing treatments for severe rare medical conditions. The company's primary therapeutic focus is apraglutide, a prolonged-acting synthetic peptide analog of glucagon-like peptide-2. This compound is currently in a Phase III clinical trial for individuals with short bowel syndrome-intestinal failure (SBS-IF), and is also being evaluated in a Phase II clinical trial for SBS-IF patients with colon-in-continuity anatomy. Furthermore, apraglutide is undergoing a Phase II clinical study for patients experiencing steroid-refractory gastrointestinal acute graft-versus-host disease (aGvHD). Founded in 2019, VectivBio's corporate headquarters are situated in Basel, Switzerland.
Aandeelprijs
$16.85
Laatst gesynchroniseerd: 2023-07-07
Marktkapitalisatie
$393.50M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
CH
Handel VectivBio Holding AG (VECT)

Categorie

Dividendrendementgeschiedenis voor VectivBio Holding AG (VECT)
Het dividendrendement (TTM) van VectivBio Holding AG (aandelsymbool: VECT) per 2026 is: 0
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.00%
Dividendrendementgeschiedenis van VectivBio Holding AG (VECT) van 2026 tot 2026
Dividendrendement aan het einde van elk jaar (TTM)
Jaar Dividendrendement Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendrendementen (TTM) van vergelijkbare bedrijven of concurrenten
Bedrijf Dividendrendement Land
0.00%
US
0.00%
NL
2.48%
AU
0.00%
US
0.00%
CH